Fritextsökning
Innehållstyper
-
Nanexa develops depot formulation of the diabetes and obesity drug Saxenda
Uppsala-based company Nanexa has signed an agreement with a German contract research company to start a clinical study with a monthly depot of liraglutide. The ...
-
Mångmiljonböter för diagnostikbolag – vilseledde marknaden
Magnasense, tidigare Aegirbio, ska betala 12 miljoner kronor i sanktionsavgift. Det slår Finansinspektionen fast, efter en granskning som visar att bolaget uppr...
-
Life Science-podden: The perfect moment for an IPO
When is the right time to go for an IPO? What strategy is recommended in today´s rather uncertain business climate when it comes to taking your life science company public?
-
Medicinpriset till forskare bakom mRNA och första covidvaccinen
Årets Nobelpris i fysiologi eller medicin går till förhandstippade Katalin Karikó och Drew Weissman från University of Pennsylvania.
-
ZEISS Insights: Measurement of bone plates and screws
Get free access to technical paper.
-
Anna Törner: ”Orphan Designation – the "petite robe noire" of drug development”
It is easy to cling to various regulatory incentives, like orphan designation, and other expedited pathways, without understanding what they truly mean or wheth...
-
Lundaforskare tilldelas pris från Novo Nordisk Foundation
Hindrik Mulder, professor vid Lunds universitet, får Novo Nordisk Foundation Lecture Prize för sin forskning på diabetes.
-
Study: Semaglutide tablet produces weight loss
The pharmaceutical semaglutide is effective for weight loss even when given in tablet form, according to a phase 3 study.
-
Bill Gates planerar att donera mer än 200 miljarder dollar över 20 år
Microsofts medgrundare Bill Gates planerar att donera mer än 200 miljarder dollar de kommande 20 åren. Det innebär att han snabbar på sitt löfte om att skänka n...
-
The Swedish innovation model: “There is a paradox”
It is often said that Sweden is strong when it comes to innovation, but how well are we turning that innovation into actual medicines?
-
Study: Popular diabetes treatment is not associated with thyroid cancer
Concerns raised about an association between GLP-1 analogues, used to treat diabetes and obesity, and an increased risk of thyroid cancer are not supported by a...
-
Uncertainty about the government’s life science work
The government’s national coordinator for life science, Jenni Nordborg, left her position almost four months ago. No one has yet succeeded her, and now question...
-
Samuel Lagercrantz: The government’s performance in healthcare and life sciences so far
Since the change of government in Sweden, developments in the healthcare sector have shown promising signs, but the outlook in life sciences is less promising, ...
-
Swedish and Ukrainian Medical Product Agencies sign an agreement
The Directors-General of the Swedish and Ukrainian Medical Products Agencies have signed a cooperation agreement.
-
Looking for greater Nordic cooperation – “We have Norway and Finland in our sights”
How can Medicon Valley Alliance bring the big pharmaceutical companies back to the organisation? Life Science Sweden discussed this topic and others with the cl...
-
Astra Zeneca’s Sweden CEO: “We have great faith in our portfolio”
It all started with a summer job as an operator at Astra’s chemical factory in Snäckviken, just outside Södertälje. More than three decades and countless differ...
-
ZEISS Quality Innovation Days
The leading digital event from April 15-19, 2024.
-
Reccan i stort EU-projekt för tidig upptäckt av pankreascancer
Ett svenskt blodtest som utvecklas för tidig upptäckt av bukspottkörtelcancer spelar en viktig roll i ett stort, nystartat EU-projekt.
-
A green nursery for biotech rooted in the Scanian soil
Red Glead has established itself as one of Lund’s largest companies in pharmaceutical development. Life Science Sweden went to Skåne and met two of the founders...
-
Miljardavtal med Eli Lilly fick Camurus att rusa på börsen
Det svenska forskningsbolaget Camurus har ingått ett licensavtal med läkemedelsjätten Eli Lilly som potentiellt kan ge upp till 870 miljoner dollar, motsvarande...
-
Alvotech i nytt miljardavtal om biosimilarer
Stockholmsnoterade Alvotech har ingått avtal med brittiska Advanz Pharma om kommersialisering av tre biosimilarkandidater.
-
Forskningscenter stoppas på grund av brister – ”Väldigt allvarligt”
Forskning som bedrivs utan tillstånd. Bristande kvalitetssäkring. Personuppgifter som hanteras felaktigt. Kritiken mot arbetet på Center for Bionics and Pain Re...
-
Skuggredaktörer på utpekade rovtidskrifter duckar frågor
Namn på redaktörer saknas, upplevs påhittade eller är omöjliga att finna kontaktuppgifter till. När Life Science Sweden gör ett försök att söka redaktörer på ut...
-
Sweden is heavily criticised for not ordering Covid vaccine
Valneva and the EU Commission have entered into an agreement for 1.25 million doses of the company’s Covid vaccine, but Sweden has not placed an order.